Swedish Orphan Biovitrum (Sobi) has told analysts that its recombinant clotting factor product for haemophilia B achieved positive results in a Phase 3 trial, paving the way for a regulatory filing in the US in the first half of 2013. ---Subscribe to MedNous to access this article--- Clinical Research Company News
